|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Medi_Gene_AG
gptkb:Calithera_Biosciences
|
|
gptkbp:ceo
|
Herbert W. (Herb) Hooper
|
|
gptkbp:clinical_trial
|
Phase 3 trials
Phase 1 trials
Phase 2 trials
|
|
gptkbp:collaboration
|
gptkb:Astra_Zeneca
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Gilead_Sciences
gptkb:Abb_Vie
|
|
gptkbp:drug
|
gptkb:Olumiant
gptkb:Iclusig
gptkb:Jakafi
gptkb:Monjuvi
gptkb:Pemigatinib
|
|
gptkbp:employees
|
~1,500
|
|
gptkbp:focus
|
oncology
autoimmune diseases
inflammation
|
|
gptkbp:founded
|
gptkb:1991
|
|
gptkbp:founder
|
gptkb:Paul_Friedman
|
|
gptkbp:headquarters
|
gptkb:Wilmington,_Delaware
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Incyte Biosciences
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
gptkb:Novartis
|
|
gptkbp:research_areas
|
hematology
rheumatology
dermatology
gastroenterology
pulmonology
|
|
gptkbp:research_focus
|
gptkb:idiopathic_pulmonary_fibrosis
gptkb:Crohn's_disease
gptkb:systemic_lupus_erythematosus
gptkb:ulcerative_colitis
gptkb:chronic_graft-versus-host_disease
gptkb:polycythemia_vera
gptkb:Oncology
psoriasis
atopic dermatitis
myelofibrosis
|
|
gptkbp:revenue
|
$1.5 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
gptkb:INCY
|
|
gptkbp:subsidiary
|
gptkb:Incyte_Europe
gptkb:Incyte_Biosciences_International
gptkb:Incyte_Research_Institute
|
|
gptkbp:website
|
www.incyte.com
|
|
gptkbp:bfsParent
|
gptkb:Incyte_Corporation
|
|
gptkbp:bfsLayer
|
5
|